A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Clinical Trial Information

Trial Phone: 321-841-7246

Principal Investigator: Abhishek Chilkulwar, MD

Phase: I/II

Age Group: ADULTOLDER_ADULT

ClinicalTrials.gov ID: NCT03013998

Objective

To determine the feasibility of completing molecular, immunophenotypic, and/or biochemical studies for older AML patients in less than 7 calendar days To determine the feasibility of assigning these patients to a novel therapeutic treatment group in one of several sub-studies in this M1 Master Protocol, based on this result. To determine the clinical efficacy (defined in each sub-study) of each novel treatment strategy.

Share:

Related Clinical Trials

Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy Followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-Rearranged or NPM1-Mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: A Double-Blind Phase III Study
An Interventional Phase Ib/II Study to Evaluate the Safety and Efficacy of PF-08634404 Monotherapy and in Combination with Other Anticancer Agents in Adult Participants with Locally Advanced or Metastatic Renal Cell Carcinoma
Percutaneous or Endoscopic Gallbladder Drainage: The PEG Trial
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, PARALLEL GROUP, MULTICENTER STUDY WITH OPEN-LABEL EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF FENFLURAMINE HYDROCHLORIDE IN STUDY PARTICIPANTS WITH RETT SYNDROME